4D Pharma underlines safety and potential efficacy of asthma drug at conference

Francesca Morgan
Vox Newswire
07:56, 17th May 2022

The pharmaceutical company 4D Pharma (DDDD Follow | DDDD) has told investors that it will present an update from the phase I/II trial of its putative asthma treatment at an industry conference.

4D Pharma, which develops live biotherapeutic products (LBPs), a class of drug derived from the microbiome, explained that the data will be delivered as a late-breaking abstract, which will underline the safety and efficacy of its asset MRx-4DP0004 for its treatment in asthma.

The clinical results of MRx-4DP0004 treatment to date have reinforced 4D pharma’s success in using the MicroRx platform to select single strain LBPs and generate clinical candidates with specific immune-modulating therapeutic functionality, the company told investors today.

“We are proud to share with the asthma medical community our growing body of data supporting the potential of MRx-4DP0004 as a novel oral treatment for asthma,” it noted.

4D previously announced topline safety and efficacy data from Part A of the trial, in addition to disclosing that this portion of the trial had met the primary endpoint of safety and tolerability.

Stock Chart | DDDD


MRx-4DP0004, which has been derived from ‘good’ bacteria, was found to be well-tolerated with no treatment-related severe adverse events. This analysis will be presented to delegates at the American Thoracic Society (ATS) International Conference between 13-18 May 2022.

At the end of treatment, researchers found that 83.3% of subjects receiving MRx-4DP0004 had improved asthma control questionnaire scores compared to those receiving placebo.

The Phase I/II trial of MRx-4DP0004 is now progressing into Part B, which will assess clinical and biomarker activity in up to 90 adult patients with partly controlled asthma, 4D outlined.

Following the successful conclusion of Part A, 4D pharma intends to enrol patients into Part B of the study who are more symptomatic than those enrolled in Part A. 4D said it expects the more symptomatic patients to give even greater scope for treatment effects to be observed.

Follow News & Updates from 4D Pharma here: Follow | DDDD


Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Recent Articles